Porrata Luis F, Ansell Stephen M, Micallef Ivana N, Johnston Patrick B, Villasboas Jose C, Paludo Jonas, Durani Urshila, Markovic Svetomir N
Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA.
Department of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Biomedicines. 2024 Aug 9;12(8):1808. doi: 10.3390/biomedicines12081808.
The infusion autograft absolute number of inhibitory killer immunoglobulin-like receptor (KIR) 2DL2 and activating natural killer (NK)p30 cells are predictors of clinical outcomes in lymphoma patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). To assess if the long-term recovery of these NK cell subsets still holds clinical relevance, we set up to investigate their prognostic ability at day 100 post-APBHSCT. This was a retrospective single-institution study including 107 patients from our prior phase III trial who had a clinical assessment at day 100 post-APBHSCT. The median follow-up from day 100 was 168.19 months (interquartile range: 156.85-181.28 months). Patients with day 100 inhibitory KIR2DL2 < 0.08 cells/µL and activating NKp30 ≥ 0.19 cells/µL experienced superior overall survival (OS) and progression-free survival (PFS). A multivariate analysis revealed both the day 100 inhibitory KIR2DL2 [OS: HR = 1.449, 95%CI, 1.231-1.895, < 0.013; and PFS: HR = 2.069, 95%CI, 1.134-3.775, < 0.021] and activating NKp30 [OS: HR = 4.985, 95%CI, 2.614-9.506, < 0.0001; and PFS: HR = 4.661, 95%CI, 2.598-8.393, < 0.0001] were independent predictors for OS and PFS. Inhibitory KIR2DL2 and activating NKp30 NK cells at day 100 are prognostic immune biomarkers in lymphoma patients treated with APBHSCT.
输注自体移植物中抑制性杀伤细胞免疫球蛋白样受体（KIR）2DL2和活化性自然杀伤（NK）p30细胞的绝对数量是接受自体外周血造血干细胞移植（APBHSCT）的淋巴瘤患者临床结局的预测指标。为了评估这些NK细胞亚群的长期恢复是否仍具有临床相关性，我们着手研究它们在APBHSCT后第100天的预后能力。这是一项回顾性单机构研究，纳入了我们先前III期试验中的107例患者，这些患者在APBHSCT后第100天进行了临床评估。从第100天开始的中位随访时间为168.19个月（四分位间距：156.85 - 181.28个月）。APBHSCT后第100天抑制性KIR2DL2＜0.08细胞/μL且活化性NKp30≥0.19细胞/μL 的患者总生存期（OS）和无进展生存期（PFS）更佳。多因素分析显示，APBHSCT后第100天的抑制性KIR2DL2 [OS：风险比（HR）= 1.449，95%置信区间（CI），1.231 - 1.895，P＜0.013；PFS：HR = 2.069，95%CI，1.134 - 3.775，P＜0.021] 和活化性NKp30 [OS：HR = 4.985，95%CI，2.614 - 9.506，P＜0.0001；PFS：HR = 4.661，95%CI，2.598 - 8.393，P＜0.0001] 均是OS和PFS的独立预测因素。APBHSCT后第100天的抑制性KIR2DL2和活化性NKp30 NK细胞是接受APBHSCT治疗的淋巴瘤患者的预后免疫生物标志物。
